Publication Name	World Journal of Clinical Oncology
Manuscript ID	95642
Country	China

Received	2024-04-15 08:41
Peer-Review Started	2024-04-15 08:41
To Make the First Decision
Return for Revision	2024-09-17 03:03
Revised	2024-09-28 04:35
Second Decision	2024-10-22 02:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-22 13:30
Articles in Press	2024-10-22 13:30
Publication Fee Transferred	2024-10-24 12:54
Edit the Manuscript by Language Editor	2024-11-20 06:05
Typeset the Manuscript	2024-11-29 06:55
Publish the Manuscript Online	2024-12-11 10:19

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Wei-Wu Chen, Yue-Hong Kong and Li-Yuan Zhang
ORCID	Author(s) ORCID Number Li-Yuan Zhang http://orcid.org/0000-0002-2710-1245
Funding Agency and Grant Number	Funding Agency Grant Number The Suzhou Medical Center No. Szlcyxzx202103 The National Natural Science Foundation of China No. 82171828 The Key R and D Plan of Jiangsu Province (Development of Social) No. BE2021652 The Subject Construction Support Project of The Second Affiliated Hospital of Soochow University No. XKTJHRC20210011 The Wu Jieping Medical Foundation No. 320.6750.2021-01-12 The Special Project of "Technological Innovation" Project of CNNC Medical Industry Co. Ltd No. ZHYLTD2021001 The Suzhou Science and Education Health Project No. KJXW2021018 Foundation of Chinese Society of Clinical Oncology No.Y-pierrefabre202102-0113 The Beijing Bethune Charitable Foundation No. STLKY0016 The Research Projects of China Baoyuan Investment Co. Ltd No. 270004 Foundation of Chinese Society of Clinical Oncology No.Y-XD202002/zb-0015 The Open Project of State Key Laboratory of Radiation Medicine and Protection of Soochow University No. GZN1202302 The Suzhou Gusu Health Talent Program No. GSWS2022028 The New Medical Technology Project of the Second Affiliated Hospital of Soochow University No. 23zl001 The Multi-center Clinical Research Project for Major Diseases in Suzhou No. DZXYJ202304 The Postgraduate Research and Practice Innovation Program of Jiangsu Province No. SJCX24_1814 The Gusu Health Talent Research Fund No. GSWS2022053 The National Natural Science Foundation of China No. 82102824 The Scientific Research Program for Young Talents of China National Nuclear Corporation
Corresponding Author	Li-Yuan Zhang, PhD, Chief Physician, Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Suzhou 215000, Jiangsu Province, China. zhangliyuan@suda.edu.cn
Key Words	Nasopharyngeal carcinoma; Bone metastasis; Radiotherapy; Programmed cell death protein 1 inhibitors; Denosumab; Case report
Core Tip	Bone is a common metastatic site in nasopharyngeal carcinoma (NPC). We report a patient with NPC who developed multiple bone metastases and soft tissue invasion after one year of curative chemoradiotherapy and targeted therapy. Due to severe bone marrow suppression from prior chemotherapy, the patient declined further treatment and received denosumab (receptor activating factor ligand inhibitor) combined with PRaG therapy. This regimen resulted in progression-free survival of 16 months and overall survival of more than 35 months, without any grade 2 or higher treatment-related adverse reactions, suggesting a novel therapeutic strategy for patients with refractory NPC.
Publish Date	2024-12-11 10:19
Citation	<p>Chen WW, Kong YH, Zhang LY. Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report. <i>World J Clin Oncol</i> 2025; 16(2): 95642</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i2/95642.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i2.95642

Full Article (PDF)	WJCO-16-95642-with-cover.pdf
CARE Checklist–2016	95642-CARE-Checklist-2016.pdf
Manuscript File	95642_Auto_Edited_013504.docx
Answering Reviewers	95642-answering-reviewers.pdf
Audio Core Tip	95642-audio.mp3
Conflict-of-Interest Disclosure Form	95642-conflict-of-interest-statement.pdf
Copyright License Agreement	95642-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	95642-foundation-statement.pdf
Signed Consent for Treatment Form(s) or Document(s)	95642-informed-consent-statement.pdf
Non-Native Speakers of English Editing Certificate	95642-non-native-speakers.pdf
Peer-review Report	95642-peer-reviews.pdf
Scientific Misconduct Check	95642-scientific-misconduct-check.png
Scientific Editor Work List	95642-scientific-editor-work-list.pdf
CrossCheck Report	95642-crosscheck-report.pdf